Nano-Enabled Toxicity of Pharmaceutical Excipients
Nanotechnology has brought revolutionary advances in the pharmaceutical field. Among drug delivery systems, nanocarriers, which enhance the solubility, stability and
Category: CD as API
Cyclarity Unveils First-Ever Clinical Data Demonstrating Excretion of Oxidized Cholesterol, at American Heart Association Vascular Discovery Scientific Sessions
Cyclarity Therapeutics, Inc., a clinical stage biopharmaceutical company engineering cyclodextrin molecules into simple, scalable, and affordable therapies that bind and
CDs as Modulators of Regulated Cell Death: Implications for Immunometabolism and Therapeutic Innovation
This review critically examines how cyclodextrins modulate regulated cell death pathways and the implications for immunometabolism and therapeutic translation. Increasing
HPBCD against acute and subacute infarcts in a mouse model of ischemic stroke
HPβCD has also been investigated as an active pharmaceutical ingredient (API) for the prospective treatment of ischemic stroke. We previously
Sugammadex analog water soluble BCD polymer for peptide complexes
In this work, an integrated biophysical and biological study is presented describing both the structural and biological features of the
Sugammadex vs Neostigmine: Effects on Obese Patients’ Recovery
Compared with neostigmine, sugammadex promotes faster neuromuscular recovery, but its impact on diaphragmatic function and respiratory recovery in the morbidly
Sugammadex vs Neostigmine for Reversal of Neuromuscular Blockade and Association with Postoperative Atelectasis After Video-Assisted Thoracoscopic Surgery: A Propensity Score-Matched Cohort Study
Atelectasis means a collapse of the whole lung or an area of the lung. It’s one of the most common breathing
HPβCD’s Promise in Treating Ischemic Stroke
Ischemic stroke is a leading cause of mortality and long-term disability worldwide, with limited pharmacological interventions available. 2-hydroxypropyl-β-cyclodextrin (HPβCD), a
Phosphorylated Beta-cyclodextrin as a New Bone-Targeting Drug Delivery System Could Change the Treatment of Osteoporosis and Other Bone Diseases
Researchers in Japan have developed a promising new drug delivery platform that not only carries medicines directly to bone, but
Recent papers on Cyclodextrins in Nature
In Scientific Reports, a Japanese team investigated these effects for α-CD derivatives with various replaced substituents from the perspective of